We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Hand-Held Biosensor Device Could Enable Immediate, Sensitive Point-of-Care Detection of SARS-CoV-2 from Saliva

By LabMedica International staff writers
Posted on 02 Feb 2021
A handheld biosensor that instantaneously detects viruses and disease in saliva could revolutionize point-of-care (POC) COVID-19 testing.

Blink Science, Inc. More...
(Jacksonville, FL, USA) will soon bring to market, blinkTEST, a handheld biosensor device that can immediately detect COVID-19, and other disease biomarkers in saliva. Most POC testing devices currently available, or that have received Emergency Use Authorization (EUA), provide tests in well over 20-30 minutes. Blink is developing a low-cost, high-tech device that will provide an immediate testing response. The system will provide health reports that can be analyzed immediately to ensure rapid and precise diagnosis for acute and chronic conditions that impact people worldwide. blinkTEST will give instantaneous results without requiring costly genetic testing.

The blinkTEST biosensor reads the electrical charges between antibodies and an easy-to use test strip. And while the initial usages will be to combat COVID-19, the technology has also been tested in the lab with extremely low concentrations of proteins secreted during myocardial infarcts (heart attacks) and to detect cerebrospinal fluid, indicating that this novel testing approach could be applied to a broad set of existing diagnostic. The unique test strips will be capable of molecular detection of antigen-antibody binding and can deliver qualitative and, in some cases, highly sensitive quantitative data.

The modular technology platform will be capable of testing for multiple infectious agents (viral, bacterial, and parasitic), disease-related proteins (cardiac disease and potentially cancer), and chemicals (substance abuse or environmental contaminants) within or external to the body using saliva, urine, blood, or other biological samples. This fundamental breakthrough in bioelectronic molecular testing is instant, reliable, inexpensive (pennies per strip), ultra-sensitive (ng/ml), highly specific, and portable. The product is not yet currently available for use in the US and is in the preparation phase of being submitted to the FDA for an EUA.

“What we are bringing to market is revolutionary. This device will be able to provide the fastest test not only for COVID-19, but also for a number of other viruses and specific disease states” said Blink Science CEO and president, Eric Doherty.

Related Links:
Blink Science, Inc.


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.